Name: Living with Narcolepsy: Saturday Support Group
Start: 2025-08-02T13:30:00-04:00
End: 2025-08-02T14:30:00-04:00
Location: HeyPeers Website

May 02 2023
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

Posted at May 02 2023
h in News by Cara Weaver

Avadel Pharmaceuticals May 1 2023 PDF

https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-final-fda-approval-lumryztm

Print page

May 02 2023 Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

0 events, 29

0 events, 29

2 events, 30

2 events, 30

1 event, 1

1 event, 1

2 events, 2

2 events, 2

1 event, 3

1 event, 3

1 event, 4

1 event, 4

1 event, 5

1 event, 5

0 events, 6

0 events, 6

2 events, 7

2 events, 7

1 event, 8

1 event, 8

2 events, 9

2 events, 9

1 event, 10

1 event, 10

1 event, 11

1 event, 11

1 event, 12

1 event, 12

0 events, 13

0 events, 13

2 events, 14

2 events, 14

1 event, 15

1 event, 15

2 events, 16

2 events, 16

1 event, 17

1 event, 17

1 event, 18

1 event, 18

1 event, 19

1 event, 19

0 events, 20

0 events, 20

2 events, 21

2 events, 21

1 event, 22

1 event, 22

2 events, 23

2 events, 23

2 events, 24

2 events, 24

1 event, 25

1 event, 25

1 event, 26

1 event, 26

0 events, 27

0 events, 27

2 events, 28

2 events, 28

1 event, 29

1 event, 29

May 02 2023
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy